China's CDE accepts GSK's regulatory filing for RSV vaccine.
Drugmaker GSK said on Tuesday that China's Center for Drug Evaluation has accepted its regulatory filing for Arexvy, its recombinant, adjuvanted respiratory syncytial virus vaccine, for the prevention of lower respiratory tract disease in adults aged 60 and over.
GSK
10 February 2026 07:49:47
Source: Sharecast
GSK noted that, if approved, it would become the first RSV vaccine available to this age group in China to help protect against the "potentially serious consequences" of RSV.
The FTSE 100-listed firm noted that the submission was supported by a broad data package, including positive Phase III results from a trial in adults aged 60 and above in China, in which all primary endpoints were met and the vaccine showed an acceptable safety profile.
GSK added that a regulatory decision was expected to be made in 2027.
Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.
